Monday’s Top Biotech Stocks to Watch: Rockwell, AbbVie, Shire, Allergan, and Valeant

Rockwell Medical, AbbVie, Shire, Allergan, and Valeant could all loom large in health care headlines this morning.

Jun 23, 2014 at 9:20AM


Let's take a look at five stocks -- Rockwell Medical (NASDAQ:RMTI), AbbVie (NYSE:ABBV), Shire (NASDAQ:SHPG), Allergan (NYSE:AGN), and Valeant Pharmaceuticals (NYSE:VRX) -- which could all loom large in health care headlines this Monday morning.

FDA approves Rockwell Medical's Calcitriol
Rockwell Medical is up nearly 8% in pre-market trading after the FDA approved Calcitriol, its low-cost vitamin D injection for patients undergoing chronic renal dialysis. Vitamin D deficiency is common in dialysis patients, and can cause elevated parathyroid hormone levels (PTH) which lead to various bone and joint problems. During clinical trials, Calcitriol was shown to significantly reduce PTH levels.

The majority of Rockwell Medical's revenue is generated by hemodialysis concentrates and dialysates. Investor interest in two newer products -- Triferic and Calcitriol -- have caused the stock to rally 190% over the past 12 months.

Triferic is currently under FDA clinical review as an iron replacement treatment for dialysis patients. The FDA has scheduled a PDUFA action date for Triferic on January 24, 2015.

Triferic is expected to generate annual peak sales of $150 million to $250 million, and Calcitriol is expected to generate annual sales between $20 million to $138 million -- both of which would be big boosts for Rockwell, which only reported $52.4 million in sales in 2013.

AbbVie reportedly mulling a new bid for Shire
Meanwhile, AbbVie is reportedly mulling a new takeover bid for Shire after its $46.3 billion offer was rejected last week. Shire stated that the offer -- the third unsolicited one from the AbbVie -- significantly undervalued the company. Shire has also published "The Path to U.S. $10 Billion in Product Sales by 2020" on its website to explain why AbbVie's offer was too low.

AbbVie is now considering a new bid. Acquiring Shire would benefit AbbVie in three major ways.

First, it would allow Illinois-based AbbVie to move its tax domicile to Ireland, where Shire is based, resulting in lower corporate taxes. Second, it would gain Shire's lucrative portfolio of ADHD drugs, which accounted for 41% of its revenue last year. Sales of Shire's top ADHD drug, Vyvanse, rose 19% year-over-year in 2013 to $1.2 billion and is expected to hit peak sales of $3.5 billion. Third, Shire acquired ViroPharma last year, which added Cinryze, the only approved preventative treatment for hereditary angioedema (HAE), to its portfolio. Cinryze is expected to generate peak sales of around $600 million based on North American sales alone.

Shire's ADHD drugs and Cinryze would help AbbVie diversify its portfolio away from its blockbuster rheumatoid arthritis drug Humira, which accounted for more than half of its $18.8 billion top line last year with $10.7 billion in sales. However, Humira will lose U.S patent protection in late 2016.

Investors should note that AbbVie is not Shire's only potential suitor. Allergan, which is now being targeted by Valeant, is also reportedly interested in acquiring the company.

Allergan rejects Valeant again
Speaking of Allergan, the company's board of directors just rejected Valeant's latest takeover offer of $72 in cash plus 0.83 shares of Valeant for each share or Allergan -- for a total value of $52.7 billion.

Allergan's reason was the same as before -- it believes that Valeant undervalues the company and creates significant risks for Allergan shareholders. The company has strongly recommended that Allegan shareholders to not tender any of their shares to Valeant.

Valeant is trying to acquire Allergan for two key reasons -- its cosmetic and eye drugs. Allergan is guiding for its top cosmetic drug, Botox, to generate $2.18 billion to $2.28 billion in sales in 2014. Allergan's top eye drug, Restasis, is expected to generate sales of roughly $1 billion by the end of the year.

Valeant has been pursuing an aggressive strategy of inorganic growth over the past few years. It acquired eye care giant Bausch & Lomb in 2013, then acquired a portfolio of cosmetic and dermatological products through its acquisitions of Solta Medical and Medicis Pharmaceutical.  

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information